Signal licenses heart failure drug patent
Aberdeen patent for heart failure drugs licensed to Signal Pharma
A patent for novel drugs to treat heart disease has been licensed by the University of Aberdeen to Signal Pharma. These drugs have been the subject of many years work by synthetic chemists at the Kosterlitz Centre for Therapeutics. The compounds are believed to work by switching cardiac metabolism from fats to glucose, thus increasing the amount of energy generated per unit oxygen and permitting the failing heart to maintain output. The drugs may find use in a wide range of cardiovascular conditions, from angina to type-2 diabetes; however, our main interest is the treatment of diastolic heart failure, a condition with 5-year mortality worse than most cancers, for which there are no currently-available pharmacotherapies.